CME-accredited webinar | Interdisciplinary guidelines for myotonic dystrophy type 1 (DM1) management across the spectrum
NMD4C and Muscular Dystrophy Canada (MDC) are pleased to invite you to a webinar on interdisciplinary guidelines for myotonic dystrophy type 1 (DM1).
This webinar is CME-accredited. The NMD Rounds & Educational Webinars is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organizational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
Tuesday, October 6th at 5:00pm ET
If you have any questions, please email
Register HERE
Objectives:
At the end of the presentation, the attendees will be able to identify:
- Key management areas among the most frequent phenotypes of DM1
- Key treatment perspectives in DM1
- Life-threatening complications related to DM1 management
Topics and speakers:
International clinical guidelines for adult DM1: An allied health perspective
Dr. Cynthia Gagnon (NMD4C investigator)
Exercise prescription for adult DM1: What do we know?
Dr. Élise Duchesne (NMD4C member)
International clinical guidelines for congenital DM1
Dr. Craig Campbell (NMD4C investigator) and Dr. Cam-Tu Nguyen
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.